|
KMID : 0370220200640050369
|
|
Yakhak Hoeji
2020 Volume.64 No. 5 p.369 ~ p.376
|
|
|
Disease Burden of Non-Hodgkin Lymphoma
|
|
Park Hae-Young
An Se-Na
Jeon Soo-Min
Kwon Jin-Won
|
|
|
Abstract
|
|
|
|
Studies on the burden of disease for the patients with non-Hodgkin’s lymphoma (NHL) which accounts forabout 90 percent of lymphoma are still insufficient. Thus, this study was conducted to assess mortality and economicburden of NHL overall and subtypes. This analysis based on a sample cohort database from the National Health InsuranceSharing Service. ICD-10 codes were used to select NHL patients (C82-86, C96) and to classify subtype of NHL. Aretrospective cohort design was applied and patients and their matching controls were compared on survival and medicalexpenditure using Cox hazard proportion model and generalized linear regression. The 5-year survival rates were 66.2%in NHL total patients (n=521) and 61.7% in diffuse large B-cell lymphoma and male and aged ≥80 showed higher riskfor survival. The 5-year cumulative medical expenditure after first diagnosis of NHL was 37.1 million won, and about44% of the expenses were spent during the first year. The 5-year costs were 4.09 times higher than those of controls, andcomorbidity index, older age, and death increased the medical expenditure. In conclusion, NHL caused lower survival andhigher medical costs compared to the non-cancer controls, and this study confirmed that subtype of NHL, gender, age,comorbidity and death had a significant impact on the burden of the disease.
|
|
|
KEYWORD
|
|
|
mortality, survival analysis, non-Hodgkin lymphoma, B-cell lymphoma, diffuse large B-cell lymphoma, costs and cost-analysis, disease burden
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|